Budesonide with Formoterol Inhalers: Doses, MART and What the Trials Show

Budesonide combined with formoterol is the only inhaled corticosteroid and long-acting beta agonist pairing that can be used both as daily maintenance treatment and as the rescue inhaler. That single property, which comes from formoterol rather than from budesonide, is the reason this combination sits at the centre of modern asthma treatment while other combination inhalers do not.

Most guides describe the drug. This one covers what the trials measured, what the numbers on the box mean, and where the combination stops being the right choice.

What is in the inhaler

Two drugs with different jobs and very different timescales.

Budesonide is an inhaled corticosteroid. It suppresses airway inflammation, which is the underlying process in asthma. It does nothing acutely. Budesonide is a 1:1 racemic mixture of two epimers, 22R and 22S, and is formulated as a pressurised metered dose inhaler, a dry powder inhaler and a nebuliser solution, with meaningful differences in how much drug reaches the lung between them (PMID: 11475468).

Formoterol is a long-acting beta-2 agonist that relaxes airway smooth muscle. Its defining property is that it combines a long duration with a fast onset, within a few minutes. Salmeterol, the other common long-acting beta agonist, is long acting but slow in onset, which is why it can never be used as a reliever.

Putting them in one device is not just packaging convenience. A patient handed a steroid inhaler and a separate reliever will predictably use the reliever, because it produces an immediate sensation of relief and the steroid does not. Combining them means every rescue dose also delivers an anti-inflammatory dose. Concurrent use of the two does not alter the pharmacokinetic or pharmacodynamic profile of either drug, or their adverse effect profiles (PMID: 11217872).

The regimen that changed the guidelines

Until 2019, standard practice for mild asthma was a short-acting beta agonist alone, used when symptoms appeared. The Global Initiative for Asthma no longer recommends short-acting beta agonist monotherapy at any step, and names as-needed inhaled corticosteroid with formoterol as preferred reliever therapy for adults and adolescents with mild asthma. The stated reasons are the risks of reliever-only treatment, the reduction in severe attacks that inhaled corticosteroid and formoterol reliever therapy produces, and a favourable risk to benefit profile against maintenance steroid plus separate reliever (PMID: 38237858).

That is a large change and it rests on trial data rather than on opinion.

SYGMA 1: the adult numbers

A 52-week double-blind trial randomised 3,849 patients aged 12 and over with mild asthma to one of three regimens: as-needed terbutaline (a short-acting reliever) with twice-daily placebo, as-needed budesonide 200 mcg with formoterol 6 mcg, or twice-daily maintenance budesonide 200 mcg with as-needed terbutaline. 3,836 patients entered the analysis (PMID: 29768149).

Outcome	As-needed terbutaline	As-needed budesonide-formoterol	Maintenance budesonide
Weeks with well-controlled asthma	31.1%	34.4%	44.4%
Annual rate of severe exacerbations	0.20	0.07	0.09
Median metered daily steroid dose	None	57 mcg	340 mcg

The exacerbation column is the one that matters. As-needed budesonide with formoterol cut the severe exacerbation rate to roughly a third of the reliever-only rate, with a rate ratio of 0.36 (95 percent CI 0.27 to 0.49). Against daily maintenance budesonide the rate ratio was 0.83 (95 percent CI 0.59 to 1.16), meaning the two were statistically indistinguishable on attacks.

It achieved that on 57 mcg of budesonide per day against 340 mcg for the maintenance arm, which is 17 percent of the steroid exposure for the same protection against attacks.

The symptom control column tells the other half of the story. On weeks with well-controlled asthma, as-needed budesonide-formoterol beat the reliever-only arm by a narrow margin (odds ratio 1.14, 95 percent CI 1.00 to 1.30, P=0.046) but lost clearly to daily maintenance budesonide (odds ratio 0.64, 95 percent CI 0.57 to 0.73). Daily maintenance treatment controls day-to-day symptoms better. As-needed combination treatment matches it on preventing attacks at a fraction of the steroid dose. Those are different trade-offs, and they explain why guidelines describe options rather than issuing one instruction.

One number in that trial deserves attention on its own: adherence in the maintenance arm was 78.9 percent, and that is adherence inside a monitored clinical trial. Real-world adherence to twice-daily preventer inhalers is considerably lower. A regimen that only works when taken every day competes against a regimen that is taken exactly when the patient feels a reason to take it.

CARE: what happened when the same question was asked in children

The adult evidence was settled well before the paediatric evidence. The CARE trial was a 52-week open-label randomised trial at 15 sites in New Zealand in children aged 5 to 15 who were using a short-acting reliever alone. 360 children were randomised, 179 to budesonide 50 mcg with formoterol 3 mcg, two actuations as needed, and 181 to salbutamol 100 mcg, two actuations as needed (PMID: 41033330).

Outcome	Budesonide-formoterol (n=179)	Salbutamol (n=181)
Asthma attacks per child per year	0.23	0.41
Relative rate	0.55 (95% CI 0.35 to 0.86), p=0.012
Participants with at least one adverse event	91%	92%

A 45 percent reduction in attacks with an essentially identical adverse event rate. Note the doses used: 50 mcg budesonide with 3 mcg formoterol per actuation, which is far below any adult strength, and is not a strength stocked in most markets. That is a real limitation on translating the result directly to what is on a pharmacy shelf.

Maintenance and reliever therapy in practice

Using one inhaler for both jobs is called maintenance and reliever therapy, sometimes written as MART or SMART. In outline: a fixed number of doses morning and evening, plus additional doses of the same inhaler when symptoms occur, up to a daily maximum defined by the prescriber.

Three points that get lost in the summaries:

It only works with formoterol. A budesonide and formoterol inhaler can be used this way. A salmeterol and fluticasone inhaler cannot, because salmeterol is too slow in onset to relieve symptoms and repeated extra doses would deliver an unsafe amount of a long-acting beta agonist. Substituting one combination for the other because they look similar is a real error.

The daily maximum is not a formality. Every maintenance and reliever protocol specifies a total number of actuations per day and a threshold above which the patient must seek medical review. Repeatedly hitting the ceiling means the asthma is not controlled, and the correct response is assessment rather than continuing to dose.

The regimen is not for everyone. Patients who cannot follow a variable dosing schedule, and anyone whose asthma is unstable enough to need oral steroids, need a plan set by their own prescriber, not a general protocol from an article.

Reading the numbers on the box

Two naming conventions are in circulation and they are not directly comparable.

The Foracort range names the budesonide content per actuation or capsule, with formoterol fixed at 6 mcg. Foracort 100, 200 and 400 correspond to 100, 200 and 400 mcg of budesonide.

Symbicort Turbuhaler names both drugs. The strengths we stock are 80 mcg with 4.5 mcg, 160 mcg with 4.5 mcg, and 320 mcg with 9 mcg.

Product	Strength	Device	Price
Foracort 100 Inhaler	100 mcg budesonide	Metered dose inhaler	$9.00
Foracort 200 Inhaler	200 mcg budesonide	Metered dose inhaler	$21.00
Foracort 400 Inhaler	400 mcg budesonide	Metered dose inhaler	$26.00
Foracort 200 Rotacap	200 mcg budesonide	Dry powder capsule	$24.00
Symbicort 160 Turbuhaler	160 mcg with 4.5 mcg	Dry powder inhaler	$30.00
Symbicort 320 Turbuhaler	320 mcg with 9 mcg	Dry powder inhaler	$40.00

Where the strengths sit against steroid dose categories

Inhaled corticosteroid doses are conventionally grouped as low, medium and high total daily dose. For budesonide by dry powder inhaler in adults and adolescents, the categories used by the Global Initiative for Asthma are approximately 200 to 400 mcg per day for low, above 400 up to 800 mcg for medium, and above 800 mcg for high. For children aged 6 to 11 the bands are roughly half those figures.

These bands are not statements of equal potency between different steroids. They are a way of placing any given inhaler on a low, medium or high shelf so that a change of product does not silently become a change of dose. Anyone switching brand or device should have the new daily total worked out rather than assumed, because the numbers printed on two boxes can look similar and land in different bands.

Devices: the part that decides whether any of this works

A metered dose inhaler releases a pressurised spray and requires the patient to coordinate the press with a slow inhalation. Poor coordination is common and drives most of the drug into the mouth and throat. A spacer largely removes this problem and is worth having for anyone using a pressurised inhaler, especially children.

A dry powder device such as a rotahaler or turbuhaler needs no coordination but does need a fast, deep inhalation to disperse the powder. Very young children and patients in an acute attack often cannot generate it.

Breath-actuated inhalers such as the Synchrobreathe versions of Foracort 200 fire when the patient inhales, removing the coordination step while keeping the pressurised delivery.

Nebuliser respules deliver the drug over several minutes of tidal breathing and need no technique at all, which is why they are used in small children and during severe attacks, at the cost of being slow and equipment-dependent.

Device choice matters as much as strength. A high-dose inhaler used with poor technique can deliver less drug to the airways than a low-dose one used correctly.

Side effects, and which drug causes what

Splitting the side effects by component makes them easier to act on.

From the budesonide component, locally: oral thrush, hoarseness and throat irritation. These come from drug deposited in the mouth and throat, not from the drug reaching the lungs, which is why rinsing the mouth and spitting after every dose reduces them substantially. Using a spacer with a pressurised inhaler reduces them further.

From the budesonide component, systemically: relevant mainly at higher daily doses and over long periods. This is the reason the low, medium and high bands exist and the reason maintenance and reliever regimens that cut total steroid exposure are attractive.

From the formoterol component: tremor, palpitations, headache and, occasionally, muscle cramp. These are dose-related beta agonist effects and typically settle over the first days to weeks of treatment. Tremor after a rescue dose is expected pharmacology rather than an allergy.

Paradoxical bronchospasm, meaning tightening of the airways immediately after inhaling, is uncommon but is a reason to stop and seek assessment rather than to take another dose.

When the combination is not the right answer

A combination inhaler is not automatically better than a plain steroid. If asthma is well controlled on budesonide alone, adding a long-acting beta agonist adds cost and side effects without adding control. Budecort 200 and the rest of the budesonide-only range exist for that reason.

The combination earns its place when a plain inhaled steroid at an appropriate dose is not achieving control, or when a maintenance and reliever regimen is being used deliberately.

In the other direction, a combination inhaler does not remove the need for a reliever plan. If the prescribed regimen is fixed twice-daily combination treatment rather than maintenance and reliever, a separate reliever such as Asthalin or Levolin is still required, and the differences between those two are covered in our salbutamol and levosalbutamol comparison.

In moderate to severe allergic asthma that stays uncontrolled on combination treatment, biologic therapy is the next step rather than more inhaler. One trial in 88 children with moderate to severe allergic asthma added omalizumab to budesonide with formoterol and reported better pulmonary function outcomes than the inhaler alone (PMID: 37422796). Biologics are specialist-initiated and are not available over any pharmacy counter.

Practical points that change outcomes more than product choice

• Rinse and spit after every dose. This is the single highest-value habit for anyone on an inhaled steroid.
• Track reliever use. Needing rescue doses more than twice a week, on a fixed-dose regimen, means the asthma is not controlled.
• Never stop the steroid because breathing feels fine. Feeling fine on treatment is the treatment working.
• Check the counter. Pressurised inhalers keep spraying propellant after the drug has run out, so a device that still puffs is not proof that it still doses.
• Have a written action plan that states what to do when symptoms escalate, agreed with a prescriber.

Medical disclaimer

This article is educational and does not replace advice from a qualified healthcare professional. Budesonide with formoterol requires a prescription in the United States, United Kingdom, Canada and Australia. Doses quoted from clinical trials describe what was studied in those trials and are not a dosing instruction for any individual. Maintenance and reliever regimens must be set by the prescriber, including the daily maximum. Asthma symptoms that are worsening, or a reliever that is no longer helping, need urgent medical assessment.

References

• O Byrne PM et al. Inhaled combined budesonide-formoterol as needed in mild asthma. SYGMA 1, NCT02149199. PubMed PMID: 29768149.
• Budesonide-formoterol versus salbutamol as reliever therapy in children with mild asthma (CARE): a 52-week randomised controlled trial. PubMed PMID: 41033330.
• The role of ICS-containing rescue therapy versus SABA alone in asthma management today. PubMed PMID: 38237858.
• Inhaled budesonide/formoterol combination. PubMed PMID: 11217872.
• Clinical pharmacokinetics of inhaled budesonide. PubMed PMID: 11475468.
• Effects of omalizumab combined with budesonide formoterol in children with moderate and severe allergic asthma. PubMed PMID: 37422796.
• Global Initiative for Asthma, Global Strategy for Asthma Management and Prevention, inhaled corticosteroid daily dose categories.

Related reading on asthma treatment

For the oral controller option and why its safety profile is debated, see our guide to montelukast side effects and the FDA boxed warning. For reliever inhalers, see salbutamol compared with levosalbutamol. The asthma treatment overview sets out how the classes fit together, and the full range is on our asthma and respiratory medicines page.